Alain Rook

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
    A H Rook
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Blood 94:902-8. 1999
  2. ncbi request reprint The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma
    Alain H Rook
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Dermatol Ther 16:331-6. 2003
  3. ncbi request reprint Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2
    Alain H Rook
    Department of Dermatology, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Hematol Oncol Clin North Am 17:1435-48, ix. 2003
  4. ncbi request reprint Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod
    Karen Rebecca Suchin
    Department of Dermatology, Hospital of the University of Pennsylvania, 2 Rhoads Pavilion, 3600 Spruce St, Philadelphia, PA 19104 2399, USA
    Arch Dermatol 138:1137-9. 2002
  5. ncbi request reprint Denileukin diftitox for the treatment of panniculitic lymphoma
    Karen S McGinnis
    Arch Dermatol 138:740-2. 2002
  6. doi request reprint A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis
    Alain H Rook
    University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 63:984-90. 2010
  7. ncbi request reprint Photopheresis: clinical applications and mechanism of action
    A H Rook
    Department of Dermatology, The University of Pennsylvania, Philadelphia, USA
    J Investig Dermatol Symp Proc 4:85-90. 1999
  8. ncbi request reprint The role for interleukin-12 therapy of cutaneous T cell lymphoma
    A H Rook
    Department of Dermatology, University of Pennsylvania, Philadelphia 19104, USA
    Ann N Y Acad Sci 941:177-84. 2001
  9. doi request reprint High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response
    Brian A Raphael
    Department of Dermatology, The Hospital at the University of Pennsylvania, Philadelphia, USA
    Arch Dermatol 147:1410-5. 2011
  10. ncbi request reprint Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma
    Mohamed H Zaki
    Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Invest Dermatol 118:366-71. 2002

Collaborators

Detail Information

Publications60

  1. ncbi request reprint Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
    A H Rook
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Blood 94:902-8. 1999
    ..One patient discontinued rhIL-12 at week 6 because of depression. These results suggest that rhIL-12 may augment antitumor cytotoxic T-cell responses and may represent a potent and well-tolerated therapeutic agent for CTCL...
  2. ncbi request reprint The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma
    Alain H Rook
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Dermatol Ther 16:331-6. 2003
    ..In this review, the authors will summarize current knowledge regarding the use of cytokines, fusion proteins and antibodies for the treatment of cutaneous T-cell lymphoma...
  3. ncbi request reprint Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2
    Alain H Rook
    Department of Dermatology, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Hematol Oncol Clin North Am 17:1435-48, ix. 2003
    ....
  4. ncbi request reprint Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod
    Karen Rebecca Suchin
    Department of Dermatology, Hospital of the University of Pennsylvania, 2 Rhoads Pavilion, 3600 Spruce St, Philadelphia, PA 19104 2399, USA
    Arch Dermatol 138:1137-9. 2002
  5. ncbi request reprint Denileukin diftitox for the treatment of panniculitic lymphoma
    Karen S McGinnis
    Arch Dermatol 138:740-2. 2002
  6. doi request reprint A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis
    Alain H Rook
    University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 63:984-90. 2010
    ....
  7. ncbi request reprint Photopheresis: clinical applications and mechanism of action
    A H Rook
    Department of Dermatology, The University of Pennsylvania, Philadelphia, USA
    J Investig Dermatol Symp Proc 4:85-90. 1999
    ..Treatment-induced apoptotic death of pathogenic T cells and activation of antigen presenting cells are postulated to have important effects in this therapeutic process...
  8. ncbi request reprint The role for interleukin-12 therapy of cutaneous T cell lymphoma
    A H Rook
    Department of Dermatology, University of Pennsylvania, Philadelphia 19104, USA
    Ann N Y Acad Sci 941:177-84. 2001
    ..Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12...
  9. doi request reprint High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response
    Brian A Raphael
    Department of Dermatology, The Hospital at the University of Pennsylvania, Philadelphia, USA
    Arch Dermatol 147:1410-5. 2011
    ..To quantify response rates of Sézary syndrome (SS) to multimodality immunomodulatory therapy and to identify the important prognostic parameters that affect overall response to treatment...
  10. ncbi request reprint Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma
    Mohamed H Zaki
    Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Invest Dermatol 118:366-71. 2002
    ....
  11. ncbi request reprint Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma
    Alain H Rook
    University of Pennsylvania, Philadelphia, USA
    Adv Dermatol 18:29-43. 2002
    ..Both new and old biologic response-modifying treatment options currently used to treat CTCL are reviewed...
  12. ncbi request reprint Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines
    Maria Wysocka
    Department of Dermatology, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Blood 100:3287-94. 2002
    ..Importantly, the ability of rCD40L to potently induce IL-12 production from monocytes and residual dendritic cells of SzS patients could potentially serve as an immune-restorative therapeutic agent...
  13. ncbi request reprint IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome
    Jessica S Yoon
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Invest Dermatol 128:473-80. 2008
    ..Thus, IL-21 may play an important role in enhancing the host immune response of Sézary syndrome patients through the increased cytolytic activity of T and NK cells...
  14. ncbi request reprint A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides
    Madeleine Duvic
    Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
    J Am Acad Dermatol 55:807-13. 2006
    ..Progression of mycosis fungoides is associated with Th(2) cytokines produced by a clonal proliferation of epidermotropic T-helper cells...
  15. ncbi request reprint Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms
    Karen S McGinnis
    Department of Dermatology, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA 19104 4283, USA
    J Am Acad Dermatol 50:375-9. 2004
    ..Nevertheless, this dose is typically associated with adverse effects including severe hyperlipidemia. Furthermore, there appears to be no standardization of dosing among physicians who treat CTCL...
  16. ncbi request reprint High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome
    Stephen K Richardson
    Department of Dermatology, University of Pennsylvania, Philadelphia, USA
    Clin Lymphoma Myeloma 7:226-32. 2006
    ....
  17. ncbi request reprint Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma
    Stephen K Richardson
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Cutan Med Surg 7:8-12. 2003
  18. doi request reprint Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome
    Camille E Introcaso
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 58:592-5. 2008
    ..The data from these 4 patients illustrate the potential for total skin electron beam to be used as both a skin and blood tumor debulking agent, and not merely as a palliation for skin symptoms...
  19. pmc Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes
    Monika Kasprzycka
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 181:2506-12. 2008
    ....
  20. ncbi request reprint Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma
    Michael Shapiro
    Department of Dermatology, University of Pennsylvania, Philadelphia, USA
    J Am Acad Dermatol 47:956-61. 2002
  21. doi request reprint Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression
    Sara Samimi
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Arch Dermatol 146:1382-8. 2010
    ....
  22. ncbi request reprint Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine
    Stephen K Richardson
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennysylvania, USA
    Am J Hematol 82:792-7. 2007
    ..05). Our results show that bexarotene may inhibit malignant cell trafficking to the skin through an ability to suppress CCR4 expression among Sezary syndrome lymphocytes...
  23. pmc Immunopathogenesis and therapy of cutaneous T cell lymphoma
    Ellen J Kim
    Department of Dermatology, University of Pennsylvania School of Medicine and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 115:798-812. 2005
    ....
  24. ncbi request reprint Biological effects of bexarotene in cutaneous T-cell lymphoma
    Jeanne B Budgin
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Arch Dermatol 141:315-21. 2005
    ..To determine the effects of bexarotene on malignant T cells isolated from the peripheral blood of patients with the leukemic variant of cutaneous T-cell lymphoma (Sézary syndrome)...
  25. ncbi request reprint Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1
    Stephen Richardson
    Department of Dermatology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    Arch Dermatol 141:301-4. 2005
  26. ncbi request reprint Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15
    Maria Wysocka
    Department of Dermatology, University of Pennsylvania, 245 CRB, 415 Curie Blvd, Philadelphia, PA 19104, USA
    Blood 104:4142-9. 2004
    ..These findings have important implications for the potential enhancement of antitumor immunity among patients with advanced CTCL...
  27. ncbi request reprint Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12
    Maria Wysocka
    Department of Dermatology, University of Pennsylvania, PA 19104, USA
    Clin Lymphoma Myeloma 7:524-34. 2007
    ....
  28. ncbi request reprint Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution
    Karen Rebecca Suchin
    Department of Dermatology and General Clinical Research Center, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Arch Dermatol 138:1054-60. 2002
    ..To determine the efficacy of multimodality biologic response therapy for patients with cutaneous T-cell lymphoma (CTCL)...
  29. doi request reprint Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma
    Rachel H Gormley
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Am Acad Dermatol 62:300-7. 2010
    ....
  30. doi request reprint Update on treatment of cutaneous T-cell lymphoma
    Jennifer M Gardner
    Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Oncol 21:131-7. 2009
    ..Numerous therapeutic options exist; however, many patients experience refractory disease and novel treatments are needed...
  31. doi request reprint CD8+ epidermotropic cytotoxic T-cell lymphoma with peripheral blood and central nervous system involvement
    Camille E Introcaso
    Department of Dermatology, Hospital of the University of Pennsylvania, 2 Maloney Bldg, 3400 Spruce St, Philadelphia, PA 19104, USA
    Arch Dermatol 144:1027-9. 2008
    ..To our knowledge, involvement of peripheral blood or cerebrospinal fluid with a malignant population of CD8(+) cells demonstrated by flow cytometry and T-cell receptor gene rearrangement has not been previously described...
  32. ncbi request reprint Mycosis fungoides and sezary syndrome: an update
    Ellen J Kim
    Department of Dermatology, University of Pennsylvania Health System, Philadelphia, 19104, USA
    Curr Oncol Rep 8:376-86. 2006
    ..This recent work has made a great impact on diagnosis, prognostication, and treatment. In this review, we survey the MF/SS published literature over the past year and highlight some of the important advances...
  33. ncbi request reprint Progressive epidermotropic CD8+/CD4- primary cutaneous CD30+ lymphoproliferative disorder in a patient with sarcoidosis
    Joel M Gelfand
    Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia 19102, USA
    J Am Acad Dermatol 51:304-8. 2004
    ..The combination of T-cell lymphoma and sarcoidosis is also rare and may limit treatment options...
  34. ncbi request reprint Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma
    Karen S McGinnis
    Department of Dermatology, University of Pennsylvania, Philadelphia, USA
    Arch Dermatol 139:771-5. 2003
    ..We added psoralen plus long-wave UV-A (PUVA) to this regimen in 5 patients with Sézary syndrome...
  35. doi request reprint In vivo imaging of cutaneous T-cell lymphoma migration to the skin
    Christoph Hoeller
    The Wistar Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer Res 69:2704-8. 2009
    ..However, a combination of both chemokines was required to induce extravasation of SS cells. Together, our experiments delineate the molecular adhesion cascade operant in SS cell homing to the skin in vivo...
  36. pmc Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor
    Julie H Lin
    Department of Dermatology, University of Pennsylvania, Philadelphia 19104, USA
    Blood 112:2484-8. 2008
    ..Our findings indicate that reduced expression of the RXR-alpha receptor subunit may represent a mechanism for resistance to bexarotene in T-cell malignancies...
  37. doi request reprint Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis
    Andrew B Avarbock
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 83:593-5. 2008
    ..The purpose of this case is to increase awareness and improve management of patients who are treated with denileukin diftitox with resulting vascular leak syndrome leading to hypoalbuminemia...
  38. pmc Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma
    Laszlo Kari
    Molecular Oncology Program, The Wistar Institute, 3601 Spruce St, Philadelphia, PA 19104, USA
    J Exp Med 197:1477-88. 2003
    ..Finally, we show that using 10 genes, we can identify a class of patients who will succumb within six months of sampling regardless of their tumor burden...
  39. ncbi request reprint Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using the hyper-CVAD regimen
    Michael Shapiro
    Department of Dermatology, Division of Hematology Oncology, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 74:46-51. 2003
    ..If similar results are obtained with future patients, a randomized study comparing the hyper-CVAD regimen to other therapeutic strategies may be warranted...
  40. ncbi request reprint Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome
    Camille E Introcaso
    Department of Dermatology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Am Acad Dermatol 53:428-34. 2005
    ..It has been our clinical experience that changes in patients' CD4+CD26- T-cell populations of peripheral blood lymphocytes herald changes in their clinical status...
  41. doi request reprint A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome
    Jennifer M Gardner
    Department of Dermatology, Hospital of the University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19146, USA
    J Am Acad Dermatol 61:112-6. 2009
    ..We present 3 cases of refractory Sézary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. The potential immunologic basis for this is discussed...
  42. ncbi request reprint Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas
    Michael Shapiro
    Department of Dermatology, University of Pennsylvania Health System, Philadelphia, USA
    J Am Acad Dermatol 47:623-8. 2002
    ..These preliminary data suggest that FDG-PET may be useful in determining disease activity at the time of initial diagnosis, after treatment, and evaluating a suspected recurrence...
  43. pmc T cell receptor gamma-chain gene polymerase chain reaction to diagnose central nervous system involvement by cutaneous T cell lymphoma
    Robert Taylor
    Department of Neurology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Mol Diagn 4:118-20. 2002
    ..Thus, PCR could be used early and routinely to diagnose central nervous system spread of T cell lymphomas, because of its potentially superior sensitivity and specificity to CSF cytology...
  44. ncbi request reprint Diminished expression of the type II receptor for TGFbeta (TGFbetaRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeri
    Qian Zhang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Arch Immunol Ther Exp (Warsz) 50:421-9. 2002
    ....
  45. pmc Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy
    Michael Nebozhyn
    The Wistar Institute, 3601 Spruce St, Philadelphia, PA 19104, USA
    Blood 107:3189-96. 2006
    ..These results are the first to demonstrate that gene expression profiling by quantitative PCR on a selected number of critical genes can be employed to molecularly diagnosis SS...
  46. doi request reprint Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
    Youn H Kim
    Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Program, Stanford Cancer Center, Stanford, California 94305, USA
    J Am Acad Dermatol 63:975-83. 2010
    ..PF-3512676 (formerly CPG 7909) is a Toll-like receptor 9 agonist that is being investigated for treatment of patients with advanced cancer...
  47. ncbi request reprint New biologic agents for the treatment of cutaneous T-cell lymphoma
    Carmela C Vittorio
    University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    Recent Results Cancer Res 160:321-8. 2002
    ..The new biologic response-modifying treatment options currently used to treat CTCL are reviewed...
  48. ncbi request reprint Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa
    Lars E French
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA
    J Am Acad Dermatol 49:1170-4. 2003
    ..Although not assessed in vivo in this patient, our in vitro data provide a rationale for the use of IFN-alpha in eosinophilic fasciitis and/or cellulitis...
  49. ncbi request reprint Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides
    Jin Lee
    Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Am Acad Dermatol 57:893-5. 2007
    ..We report a case of progressive multifocal leukoencephalopathy developing in an advanced mycosis fungoides patient without prior history of immunosuppressive therapy...
  50. doi request reprint Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells
    Michal Marzec
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 68:1083-91. 2008
    ....
  51. doi request reprint Stem cell transplantation in advanced cutaneous T-cell lymphoma
    Camille E Introcaso
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Am Acad Dermatol 58:645-9. 2008
    ....
  52. ncbi request reprint Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient
    Eun Ji Kwon
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 54:657-63. 2006
    ..The case also highlights the importance of clinical and pathologic examination of cutaneous lesions in the evaluation of lymphoproliferative disorders for patients undergoing transplantation...
  53. doi request reprint Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression
    Emmanuel Contassot
    Department of Dermatology, Zurich University Hospital, Zurich, Switzerland
    Blood 111:4780-7. 2008
    ..Our data on primary SzS lymphocytes reveal frequent resistance to apoptosis induced by FasL and TRAIL, which may contribute to their accumulation in patients with SzS and be relevant at a therapeutic level...
  54. ncbi request reprint CD8+ lymphoma in a patient with human immunodeficiency virus
    Chad M Hivnor
    Arch Dermatol 141:1321-2. 2005
  55. ncbi request reprint The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome
    Karen S McGinnis
    Arch Dermatol 141:1176-8. 2005
  56. ncbi request reprint Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy
    Meyeon Park
    Leuk Lymphoma 48:808-11. 2007
  57. ncbi request reprint Apoptotic responses to all-trans retinoic acid of targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sezary syndrome
    Sarah B Newton
    Arch Dermatol 143:661-2. 2007
  58. ncbi request reprint Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L
    Lars E French
    Louis Jeantet Skin Cancer Center, Department of Dermatology, Geneva University Medical School, Switzerland
    Blood 105:219-25. 2005
    ..Taken together, our results demonstrate that impaired IL-12 and TNF-alpha production in SzS is associated with defective CD4+ T lymphocyte CD40L induction and indicate that CD40L may have therapeutic potential in SzS...
  59. ncbi request reprint T cell clonality and the effect of photopheresis in systemic sclerosis and graft versus host disease
    Lars E French
    Department of Dermatology, Geneva University Medical School, Switzerland
    Transfus Apher Sci 26:191-6. 2002
    ..Furthermore, we provide initial evidence that the presence of a T cell clone in such patients may be associated with responsiveness to photopheresis...
  60. ncbi request reprint A role for regulatory T cells in cutaneous T-Cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection
    Patrick T Walsh
    J Invest Dermatol 126:690-2. 2006

Research Grants15

  1. Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma
    Alain Rook; Fiscal Year: 2009
    ..In view of our test tube results suggesting that 001/852A could stimulate antitumor responses of CTCL patients, a phase II clinical trial of this promising agent with correlative immune monitoring has been planned. ..
  2. Dendritic cell defects in cutaneous T-cell lymphoma
    Alain Rook; Fiscal Year: 2007
    ..abstract_text> ..
  3. Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma
    Alain Rook; Fiscal Year: 2006
    ..Moreover, the addition of low-dose IL-2 may yield a more efficacious combination of agents which may synergistically enhance anti-tumor immunity and clinical responses. ..
  4. CYTOKINE THERAPY OF CUTANEOUS T CELL LYMPHOMA
    Alain Rook; Fiscal Year: 2004
    ..abstract_text> ..
  5. Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma
    Alain H Rook; Fiscal Year: 2010
    ..In view of our test tube results suggesting that 001/852A could stimulate antitumor responses of CTCL patients, a phase II clinical trial of this promising agent with correlative immune monitoring has been planned. ..